PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study

OBJECTIVE: Arterial thrombosis leading to ischemic injury worsens the prognosis of many patients with cardiovascular disease. PZ-128 is a first-in-class pepducin that reversibly inhibits PAR1 (protease-activated receptor 1) on platelets and other vascular cells by targeting the intracellular surface...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuliopulos, Athan, Gurbel, Paul A., Rade, Jeffrey J., Kimmelstiel, Carey D., Turner, Susan E., Bliden, Kevin P., Fletcher, Elizabeth K., Cox, Daniel H., Covic, Lidija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Clinical and Population Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682800/
https://www.ncbi.nlm.nih.gov/pubmed/33028101
http://dx.doi.org/10.1161/ATVBAHA.120.315168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682800/
https://www.ncbi.nlm.nih.gov/pubmed/33028101
http://dx.doi.org/10.1161/ATVBAHA.120.315168

Ejemplares similares